Tag: Hatch-Waxman Act
Paragraph IV Certifications: How Generics Challenge Drug Patents
May, 16 2026Explore how Paragraph IV certifications allow generic drug makers to challenge brand-name patents under the Hatch-Waxman Act. Learn about the 180-day exclusivity, litigation risks, and strategic impacts on drug pricing.
READ MORE